You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Automated point-of-care identification of innocent Still's murmur in children

    SBC: AUSCULTECH DX LLC            Topic: NHLBI

    PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A microfluidic device for blood analysis in neonates

    SBC: Sersense Inc            Topic: NICHD

    ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Additive Manufactured PEKK Implants for Small Bone Arthroplasty

    SBC: Oxford Performance Materials, Inc.            Topic: NIAMS

    ABSTRACT This Phase I STTR is designed to evaluate the feasibility of using the OsteoFabtechnology platform for joint arthroplastyArthroFabdevicesspecifically targeting replacement of the small carpal bones in the wrist and hemiarthroplastyOsteoFabtechnology is the combination of Oxford Performance Materialsandaposproprietary formulation of polyetherketoneketoneOXPEKKpolymerand additive manufactur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. The Daily Progress System- A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTSubstance use disordersSUDsincluding opioid use disorderscontinue to be one of the most serious public health issues in the USleading to negative physical and mental health problemsfamily disruptionand premature deathAfrican Americans with drug use histories that are under criminal justice supervision are particularly vulnerable to experiencing the negative consequences associated with SUD ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    PROJECT SUMMARYZika virus, an emerging flavivirus, is associated with severe clinical outcomes, including Guillain-Barré syndrome and birth defects. Transmission of Zika virus is primarily mosquito- borne. Mosquito salivary proteins are known to enhance infectivity and pathogenesis in Zika, dengue and West Nile viruses by modulating immune responses. This proposal seeks to develop a novel vaccine ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government